AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 3629428 — intervention group
Group type: EXPERIMENTAL
Intervention: Annual chest radiographs
Number of subjects: 10040
Study 3629428 — intervention group
Group type: EXPERIMENTAL
Intervention: Sputum cytologic examinations (4-monthly)
Number of subjects: 10040
Study 3629428 — intervention group
Group type: EXPERIMENTAL
Intervention: Chest radiographs
Number of subjects: 10040
Study 3629428 — intervention group
Group type: COMPARATOR
Intervention: Sputum cytology
Number of subjects: 10040
Study 3629428 — intervention group
Group type: COMPARATOR
Intervention: Overall survival
Number of subjects: 10040
Study 29577522 — intervention group
Group type: EXPERIMENTAL
Intervention: Maastricht Acute Stress Task (MAST)
Number of subjects: 42
Study 29577522 — intervention group
Group type: COMPARATOR
Intervention: Non-stressful version of the task
Number of subjects: 42
Study 28961836 — intervention group
Group type: EXPERIMENTAL
Intervention: CAP45 (RT 45 Gy + capecitabine)
Number of subjects: 598
Study 28961836 — intervention group
Group type: COMPARATOR
Intervention: CAPOX50 (RT 50 Gy + capecitabine and oxaliplatin)
Number of subjects: 598
Study 25976690 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthrocentesis plus platelet-rich plasma (PRP) injection and then 4 consecutive PRP injections
Number of subjects: 30
Study 25976690 — intervention group
Group type: COMPARATOR
Intervention: Arthrocentesis alone (control group)
Number of subjects: 30
Study 25976690 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthrocentesis plus PRP
Number of subjects: 30
Study 22874653 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplementary snacks at school
Number of subjects: 182
Study 20833556 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B (intercostal muscle dissection technique)
Number of subjects: 60
Study 20833556 — intervention group
Group type: COMPARATOR
Intervention: Group A (intercostal nerve compression technique)
Number of subjects: 60
Study 18358590 — intervention group
Group type: EXPERIMENTAL
Intervention: G-CSF treatment
Number of subjects: 0
Study 16556754 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal shockwave treatment (1500 impulses at 16 kV in a single session)
Number of subjects: 149
Study 14505915 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal virosome vaccine adjuvanted with heat-labile toxin (HLT)
Number of subjects: 88
Study 14505915 — intervention group
Group type: COMPARATOR
Intervention: Intranasal vaccine without HLT
Number of subjects: 88
Study 14505915 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular vaccine
Number of subjects: 88
Study 10929963 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 67
Study 10929963 — intervention group
Group type: COMPARATOR
Intervention: Control (non-tamoxifen users)
Number of subjects: 67
Study 8738052 — intervention group
Group type: EXPERIMENTAL
Intervention: Casodex 50 mg monotherapy
Number of subjects: 376
Study 8738052 — intervention group
Group type: COMPARATOR
Intervention: Orchidectomy
Number of subjects: 376
Study 1582291 — intervention group
Group type: EXPERIMENTAL
Intervention: Astemizole (10 mg/ml)
Number of subjects: 16
Study 1582291 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 30730770 — intervention group
Group type: EXPERIMENTAL
Intervention: Staying Strong With Schools (SSWS)
Number of subjects: 56
Study 30730770 — intervention group
Group type: COMPARATOR
Intervention: Educational pamphlet waitlist control
Number of subjects: 56
Study 29249532 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 PUFA (0.945 g/day, 64% ALA, 21% EPA, 16% DHA)
Number of subjects: 27
Study 29249532 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 PUFA
Number of subjects: 27
Study 26347527 — intervention group
Group type: EXPERIMENTAL
Intervention: Senior trainees
Number of subjects: 32
Study 26347527 — intervention group
Group type: COMPARATOR
Intervention: Junior trainees
Number of subjects: 32
Study 26347527 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall assessment
Number of subjects: 32
Study 24390146 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose salsalate therapy for 4 weeks
Number of subjects: 58
Study 24390146 — intervention group
Group type: COMPARATOR
Intervention: Placebo therapy
Number of subjects: 58
Study 24390146 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose salsalate therapy for 4 weeks (therapeutic salicylate levels, n=31)
Number of subjects: 58
Study 24390146 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose salsalate therapy for 4 weeks (subtherapeutic salicylate levels)
Number of subjects: 58
Study 22935844 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g of intravenous L-carnitine after each dialysis session for 1 year
Number of subjects: 92
Study 22935844 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study 20825715 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant transarterial chemoembolization (TACE) within 2 months after operation
Number of subjects: 2436
Study 20825715 — intervention group
Group type: COMPARATOR
Intervention: Control group (resection only)
Number of subjects: 2436
Study 18203817 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP
Number of subjects: 36
Study 18203817 — intervention group
Group type: EXPERIMENTAL
Intervention: BVS
Number of subjects: 36
Study 16988134 — intervention group
Group type: EXPERIMENTAL
Intervention: FVJC
Number of subjects: 59
Study 16988134 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 12662379 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetyl cystein (4%) 5 ml t.i.d. for 3 days (AC group, n = 53)
Number of subjects: 107
Study 12662379 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Placebo group, n = 54)
Number of subjects: 107
Study 10965386 — intervention group
Group type: EXPERIMENTAL
Intervention: Social support intervention
Number of subjects: 363
Study 10965386 — intervention group
Group type: EXPERIMENTAL
Intervention: Education intervention
Number of subjects: 363
Study 10965386 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of social support and education
Number of subjects: 363
Study 10965386 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 363
Study 10965386 — intervention group
Group type: EXPERIMENTAL
Intervention: All intervention groups
Number of subjects: 363
Study 8890145 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 1556891 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyroplasty type I
Number of subjects: 15
Study 2869573 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta‐2 agonist terbutaline (0.50 mg)
Number of subjects: 0
Study 2869573 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta‐1 agonist prenalterol (less than or equal to 5 mg)
Number of subjects: 0
Study 2869573 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31732180 — intervention group
Group type: EXPERIMENTAL
Intervention: Upadacitinib 15 mg once daily
Number of subjects: 187
Study 31732180 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 187
Study 30292497 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic Radiographer
Number of subjects: 30
Study 30292497 — intervention group
Group type: COMPARATOR
Intervention: Doctor
Number of subjects: 30
Study 30695570 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral vinorelbine
Number of subjects: 4
Study 30695570 — intervention group
Group type: COMPARATOR
Intervention: Injectable vinorelbine
Number of subjects: 4
Study 30695570 — intervention group
Group type: COMPARATOR
Intervention: Pemetrexed
Number of subjects: 4
Study 25127717 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol Brief Intervention (BI)
Number of subjects: 0
Study 22365802 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute low dose tryptophan depletion (ATD)
Number of subjects: 26
Study 22365802 — intervention group
Group type: COMPARATOR
Intervention: Control group (T−)
Number of subjects: 26
Study 20569146 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral PrEP for HIV prevention
Number of subjects: 0
Study 20569146 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethical concerns regarding the trial
Number of subjects: 0
Study 20569146 — intervention group
Group type: EXPERIMENTAL
Intervention: General 'science exploitation' discourse
Number of subjects: 0
Study 18470787 — intervention group
Group type: EXPERIMENTAL
Intervention: Residents with the support of the Varioscope (microscope and loupe glasses with strong illumination and 7x magnification)
Number of subjects: 40
Study 18470787 — intervention group
Group type: COMPARATOR
Intervention: Consultant surgeons under standard conditions
Number of subjects: 40
Study 18470787 — intervention group
Group type: EXPERIMENTAL
Intervention: Residents with the support of the Varioscope
Number of subjects: 40
Study 18470787 — intervention group
Group type: EXPERIMENTAL
Intervention: High magnification and good lighting
Number of subjects: 40
Study 16277715 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.2% hypertonic saline hydroxyethyl starch 200/0.5
Number of subjects: 40
Study 16277715 — intervention group
Group type: COMPARATOR
Intervention: Mannitol 15%
Number of subjects: 40
Study 12433732 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-tailored information
Number of subjects: 0
Study 12433732 — intervention group
Group type: COMPARATOR
Intervention: General information
Number of subjects: 0
Study 10730531 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 grams of tuna fish oil
Number of subjects: 5
Study 10730531 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 8602477 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (treatment for subacute low back pain)
Number of subjects: 103
Study 8602477 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 103
Study 1974628 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribavirin 800 mg
Number of subjects: 164
Study 1974628 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribavirin 600 mg
Number of subjects: 164
Study 1974628 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 164
Study 7277290 — intervention group
Group type: EXPERIMENTAL
Intervention: Flow sheet design of medical record
Number of subjects: 0
Study 7277290 — intervention group
Group type: COMPARATOR
Intervention: Standard medical record (implied control)
Number of subjects: 0
Study 31559410 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced red and processed meat consumption
Number of subjects: 37
Study 28952139 — intervention group
Group type: EXPERIMENTAL
Intervention: Magill forceps
Number of subjects: 60
Study 28952139 — intervention group
Group type: COMPARATOR
Intervention: Vascular forceps with tube exchanger
Number of subjects: 60
Study 25307883 — intervention group
Group type: EXPERIMENTAL
Intervention: Indwelling urinary catheter
Number of subjects: 314
Study 25307883 — intervention group
Group type: COMPARATOR
Intervention: No urinary catheter
Number of subjects: 314
Study 24322879 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus paracasei NCC 2461 (ST11)
Number of subjects: 64
Study 24322879 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 22958738 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus with reduced CNI exposure
Number of subjects: 78
Study 22958738 — intervention group
Group type: COMPARATOR
Intervention: Standard CNI-therapy
Number of subjects: 78
Study 19203529 — intervention group
Group type: EXPERIMENTAL
Intervention: Hutex omeprazole (20 mg)
Number of subjects: 24
Study 19203529 — intervention group
Group type: COMPARATOR
Intervention: Yuhan Losec (20 mg)
Number of subjects: 24
Study 17970234 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous rasburicase at a dose of 0.02 mg/kg/day for varying durations based on serum uric acid levels (3 days for 8-10 mg/dl, 5 days for 10-15 mg/dl, 7 days for >15 mg/dl)
Number of subjects: 43
Study 17970234 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving allopurinol (not explicitly detailed in the abstract)
Number of subjects: 43
Study 16279468 — intervention group
Group type: EXPERIMENTAL
Intervention: Diffuse optical correlation methods; hand-held optical probe manually scanned over the tumor-bearing breast.
Number of subjects: 0
Study 16279468 — intervention group
Group type: COMPARATOR
Intervention: Control subjects (healthy tissue); no specific intervention mentioned.
Number of subjects: 0
Study 12113396 — intervention group
Group type: EXPERIMENTAL
Intervention: English SF-36 version
Number of subjects: 168
Study 12113396 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese SF-36 version
Number of subjects: 168
Study 12113396 — intervention group
Group type: COMPARATOR
Intervention: Both versions
Number of subjects: 168
Study 10471017 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic Touch (TT)
Number of subjects: 41
Study 10471017 — intervention group
Group type: COMPARATOR
Intervention: Control group (no TT)
Number of subjects: 41
Study 7774443 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined operative resection and immuno-chemotherapy (OIC)
Number of subjects: 121
Study 7774443 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined operative resection and immunotherapy (OI)
Number of subjects: 121
Study 7774443 — intervention group
Group type: COMPARATOR
Intervention: Combined operative resection and chemotherapy (OC)
Number of subjects: 121
Study 7774443 — intervention group
Group type: COMPARATOR
Intervention: Resection only (OP)
Number of subjects: 121
Study 2328258 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine (2 g)
Number of subjects: 10
Study 2328258 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 6158263 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylprocainamide (NAPA)
Number of subjects: 23
Study 30963446 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk of Bias assessment tool
Number of subjects: 0
Study 30963446 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpretations of judgment in the RoB tool
Number of subjects: 0
Study 30963446 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors contributing to high risk of bias
Number of subjects: 0
Study 28032810 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Classrooms intervention (movement integrated into academic lessons)
Number of subjects: 248
Study 28032810 — intervention group
Group type: COMPARATOR
Intervention: Delayed-treatment control group
Number of subjects: 248
Study 26885107 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (CTX) + Mycophenolate mofetil (MMF), n=42
Number of subjects: 82
Study 26885107 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide (CTX), n=40
Number of subjects: 82
Study 23280073 — intervention group
Group type: EXPERIMENTAL
Intervention: Citrate-containing dialysate (Cit)
Number of subjects: 23
Study 23280073 — intervention group
Group type: COMPARATOR
Intervention: Standard tinzaparin hemodialysis (tinzaparin-HD)
Number of subjects: 23
Study 20872758 — intervention group
Group type: EXPERIMENTAL
Intervention: Readiness and Motivation Therapy (RMT)
Number of subjects: 181
Study 20872758 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control condition
Number of subjects: 181
Study 19576320 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple antiplatelet regimen (aspirin plus clopidogrel plus cilostazol)
Number of subjects: 450
Study 19576320 — intervention group
Group type: COMPARATOR
Intervention: Dual antiplatelet regimen (aspirin plus clopidogrel)
Number of subjects: 450
Study 19576320 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2C19*3A allele presence
Number of subjects: 450
Study 19576320 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2C19*3
Number of subjects: 450
Study 17313501 — intervention group
Group type: EXPERIMENTAL
Intervention: H. pylori infection
Number of subjects: 3266
Study 17313501 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower socioeconomic status
Number of subjects: 3266
Study 17313501 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequent symptoms
Number of subjects: 3266
Study 17313501 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe symptoms
Number of subjects: 3266
Study 17313501 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing age
Number of subjects: 3266
Study 14751102 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Transthecal Digital Block (MTDB)
Number of subjects: 25
Study 14751102 — intervention group
Group type: COMPARATOR
Intervention: Traditional Digital Block (TDB)
Number of subjects: 25
Study 10720518 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide therapy
Number of subjects: 0
Study 9167106 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Analytic Therapy (CAT)
Number of subjects: 26
Study 9167106 — intervention group
Group type: COMPARATOR
Intervention: Diabetes Specialist Nurse Education (DSNE)
Number of subjects: 26
Study 15374367 — intervention group
Group type: EXPERIMENTAL
Intervention: Idebenone 45 mg twice daily p.o.
Number of subjects: 79
Study 15374367 — intervention group
Group type: COMPARATOR
Intervention: Oxiracetam 800 mg twice daily p.o.
Number of subjects: 79
Study 6338893 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% dextrose solution
Number of subjects: 0
Study 6338893 — intervention group
Group type: COMPARATOR
Intervention: 0.9% sodium chloride solution
Number of subjects: 0
Study 6338893 — intervention group
Group type: COMPARATOR
Intervention: Hartmann's solution
Number of subjects: 0
Study 31778196 — intervention group
Group type: COMPARATOR
Intervention: Azithromycin
Number of subjects: 4154
Study 31778196 — intervention group
Group type: COMPARATOR
Intervention: Rifaximin
Number of subjects: 4154
Study 31778196 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose antibiotic therapy
Number of subjects: 4154
Study 31778196 — intervention group
Group type: EXPERIMENTAL
Intervention: Prevent TD clinical trial
Number of subjects: 4154
Study 30134944 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment with posterior C1-C2 fusion
Number of subjects: 50
Study 30134944 — intervention group
Group type: COMPARATOR
Intervention: Non-surgical treatment with a rigid cervical collar for 12 weeks
Number of subjects: 50
Study 26970335 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.6 g omega‐3 LCPUFA supplementation
Number of subjects: 95
Study 26970335 — intervention group
Group type: COMPARATOR
Intervention: Placebo of 2.7 g soya bean oil
Number of subjects: 95
Study 26118632 — intervention group
Group type: EXPERIMENTAL
Intervention: HBV‐pulsed DCs plus entecavir
Number of subjects: 80
Study 26118632 — intervention group
Group type: COMPARATOR
Intervention: HBV‐pulsed DCs only
Number of subjects: 80
Study 26118632 — intervention group
Group type: COMPARATOR
Intervention: entecavir only
Number of subjects: 80
Study 26118632 — intervention group
Group type: COMPARATOR
Intervention: untreated control group
Number of subjects: 80
Study 21693549 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin 300-600 mg/day
Number of subjects: 106
Study 21693549 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 106
Study 20608895 — intervention group
Group type: EXPERIMENTAL
Intervention: Strict control of morning home systolic blood pressure (SBP)
Number of subjects: 80
Study 20608895 — intervention group
Group type: COMPARATOR
Intervention: Mild control of morning home systolic blood pressure (SBP)
Number of subjects: 80
Study 20608895 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine-based regimen
Number of subjects: 80
Study 20608895 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan-based regimen
Number of subjects: 80
Study 18355335 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk-free diet
Number of subjects: 12
Study 18355335 — intervention group
Group type: COMPARATOR
Intervention: Reexposure to milk
Number of subjects: 12
Study 18355335 — intervention group
Group type: COMPARATOR
Intervention: Normal diet
Number of subjects: 12
Study 15781528 — intervention group
Group type: EXPERIMENTAL
Intervention: IV fluid administration
Number of subjects: 0
Study 15781528 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid types and administration strategies
Number of subjects: 0
Study 15255625 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga practitioners (50 subjects)
Number of subjects: 100
Study 15255625 — intervention group
Group type: COMPARATOR
Intervention: Control group (50 subjects)
Number of subjects: 100
Study 10682127 — intervention group
Group type: EXPERIMENTAL
Intervention: Zalcitabine 0.75 mg every 8 hours
Number of subjects: 940
Study 10682127 — intervention group
Group type: COMPARATOR
Intervention: Saquinavir 600 mg every 8 hours
Number of subjects: 940
Study 10682127 — intervention group
Group type: COMPARATOR
Intervention: Combination zalcitabine 0.75 mg plus saquinavir 600 mg every 8 hours
Number of subjects: 940
Study 8923548 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective amputations of the angle components in the wings-in form of the Müller-Lyer illusion
Number of subjects: 0
Study 8923548 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective amputations of the angle components in the wings-out form of the Müller-Lyer illusion
Number of subjects: 0
Study 8923548 — intervention group
Group type: EXPERIMENTAL
Intervention: Method of paired comparisons and method of reproduction
Number of subjects: 0
Study 1747216 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinapril (5 mg oral twice daily, titrated to 20 mg twice daily)
Number of subjects: 97
Study 1747216 — intervention group
Group type: COMPARATOR
Intervention: Captopril (25 mg oral twice daily, titrated to 100 mg twice daily)
Number of subjects: 97
Study 402697 — intervention group
Group type: EXPERIMENTAL
Intervention: b.i.d. dosage schedule of 500 mg twice daily
Number of subjects: 327
Study 402697 — intervention group
Group type: EXPERIMENTAL
Intervention: t.i.d. dosage schedule of 250 mg three times daily
Number of subjects: 327
Study 31708422 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (0.5 mg/kg bolus before incision, followed by 0.5 mg/kg/h infusion until end of surgery)
Number of subjects: 80
Study 31708422 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 31708422 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine
Number of subjects: 80
Study 31161498 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist's intervention (PharmaFit Protocol)
Number of subjects: 44
Study 28671307 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin iontophoresis in IS groups (ABIS and SCIS)
Number of subjects: 62